Individual results may vary depending on patient-specific attributes and other factors.
Additional adverse reactions have been identified during postapproval use of JANUVIA as monotherapy and/or in combination with other antihyperglycemic agents
| BioPharma Dive, accessed February 2, 2026, Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices | AJMC, accessed February 2, 2026, Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s AMCP, accessed February 2, 2026, Eli Lilly, Novo Nordisk strike deals with White House to cut prices of weight loss drugs, accessed February 2, 2026, The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth, accessed February 2, 2026, Eli Lilly Stock Outlook: Fast-Track Oral GLP-1 Review Meets Long-Term Catalysts, accessed February 2, 2026, Beyond the Needle: Eli Lillys Orforglipron and the Small Molecule GLP-1 Revolution, accessed February 2, 2026, Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next | Cypris, accessed February 2, 2026,
According to a recent study in the Journal of the American Medical Association, roughly 12% of Americans have used GLP-1 drugs, even if unaffordable. The new Smoothie King menu is to support people taking these medicines
Monitoring the Full Health Picture The growing popularity of GLP-1 drugs has transformed obesity treatment, but clinicians emphasize that weight loss alone should not be the only measure of success
